Hyosoon Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hyosoon Park has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Hee-Yeon Woo
Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
6 shared publications - Min-Jung Kwon
Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
6 shared publications - Eun Hye Cho
Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
4 shared publications - Min-Seung Park
Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
4 shared publications - Eun Young Kim
Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
2 shared publications - In-Gu Do
Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 16 (4) , 335-343
Distribution of VerifyNow Aspirin and P2Y12 Reaction Units in Adults Undergoing Preoperative Evaluation: A Single-Institution Retrospective Study
Jungwoo Lee, M.D., Yu Jeong Choi, M.D., Jee Ah Kim, M.D., Eun Hye Cho, M.D., Min-Jung Kwon, M.D., Hee-Yeon Woo, M.D., Min-Seung Park, M.D., Hyosoon Park, M.D.. Lab Med Online 2026;16:335-43. https://doi.org/10.47429/lmo.2026.16.4.335
- 1 October 2026
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 16 (4) , 335-343
Open AccessDistribution of VerifyNow Aspirin and P2Y12 Reaction Units in Adults Undergoing Preoperative Evaluation: A Single-Institution Retrospective Study
Jungwoo Lee, M.D., Yu Jeong Choi, M.D., Jee Ah Kim, M.D., Eun Hye Cho, M.D., Min-Jung Kwon, M.D., Hee-Yeon Woo, M.D., Min-Seung Park, M.D., Hyosoon Park, M.D.. Lab Med Online 2026;16:335-43. https://doi.org/10.47429/lmo.2026.16.4.335
- 14 July 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (9) , 2008-2019
Apolipoprotein B-low-density lipoprotein cholesterol discordance refines cardiovascular risk stratification across metabolic phenotypes
- 14 July 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (9) , 2008-2019
Apolipoprotein B-low-density lipoprotein cholesterol discordance refines cardiovascular risk stratification across metabolic phenotypes
- 31 January 2026
- Published by Springer Nature in Breast Cancer
- Vol. 33 (2) , 377-385
Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer
Background Circulating tumor DNA (ctDNA) has emerged as a prognostic biomarker for breast cancer, potentially offering a more comprehensive representation of tumor genetic heterogeneity. In this study, we assessed the prognostic and monitoring values of ctDNA at multiple clinical time points during diagnosis and therapy. Methods A total of 119 patients with breast cancer underwent ctDNA analysis using next-generation sequencing, targeting 47 breast cancer-related genes at three predefined time points (baseline, post-neoadjuvant chemotherapy [post-NAC], and follow-up). Disease-free survival (DFS) was analyzed based on ctDNA status. Results ctDNA was detected in 50.9% of patients at baseline, 25.0% post-NAC, and 58.3% during follow-up. ctDNA positivity was associated with worse DFS at baseline (hazard ratio [HR] 7.54, 95% CI: 1.71–33.17, P = 0.008), post-NAC (HR 3.54, 95% CI: 1.24–10.12, P = 0.018), and follow-up (HR 7.68, 95% CI: 0.98–59.97, P = 0.052). TP53 mutations were the most frequently observed, present in 37.5%, 14.8%, and 20.4% of patients at baseline, post-NAC, and follow-up, respectively. PIK3CA mutations were the second most common, detected in 11.6%, 4.5%, and 5.8% of patients, respectively. ctDNA positivity for these mutations consistently showed elevated HRs for disease progression across clinical time points (HR range, 2.73–20.49). ctDNA non-clearance was associated with the highest risk of disease progression (HR 81.09, P < 0.001) and remained the strongest independent prognostic factor in the multivariate analysis (HR 52.07, P < 0.001). Conclusions ctDNA analysis provides significant clinical utility for prognostic stratification and disease monitoring in breast cancer management.
- 31 January 2026
- Published by Springer Nature in Breast Cancer
- Vol. 33 (2) , 377-385
Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer
Background Circulating tumor DNA (ctDNA) has emerged as a prognostic biomarker for breast cancer, potentially offering a more comprehensive representation of tumor genetic heterogeneity. In this study, we assessed the prognostic and monitoring values of ctDNA at multiple clinical time points during diagnosis and therapy. Methods A total of 119 patients with breast cancer underwent ctDNA analysis using next-generation sequencing, targeting 47 breast cancer-related genes at three predefined time points (baseline, post-neoadjuvant chemotherapy [post-NAC], and follow-up). Disease-free survival (DFS) was analyzed based on ctDNA status. Results ctDNA was detected in 50.9% of patients at baseline, 25.0% post-NAC, and 58.3% during follow-up. ctDNA positivity was associated with worse DFS at baseline (hazard ratio [HR] 7.54, 95% CI: 1.71–33.17, P = 0.008), post-NAC (HR 3.54, 95% CI: 1.24–10.12, P = 0.018), and follow-up (HR 7.68, 95% CI: 0.98–59.97, P = 0.052). TP53 mutations were the most frequently observed, present in 37.5%, 14.8%, and 20.4% of patients at baseline, post-NAC, and follow-up, respectively. PIK3CA mutations were the second most common, detected in 11.6%, 4.5%, and 5.8% of patients, respectively. ctDNA positivity for these mutations consistently showed elevated HRs for disease progression across clinical time points (HR range, 2.73–20.49). ctDNA non-clearance was associated with the highest risk of disease progression (HR 81.09, P < 0.001) and remained the strongest independent prognostic factor in the multivariate analysis (HR 52.07, P < 0.001). Conclusions ctDNA analysis provides significant clinical utility for prognostic stratification and disease monitoring in breast cancer management.
- Open Access
- 11 September 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 45 (6) , 558-561
Optimization of the Total Testing Process Within the Big Data-to-Big Data Loop
Won-Ki Min, M.D., Ph.D. and Hyosoon Park, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0238
- 11 September 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 45 (6) , 558-561
Open AccessOptimization of the Total Testing Process Within the Big Data-to-Big Data Loop
Won-Ki Min, M.D., Ph.D. and Hyosoon Park, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0238
- 31 January 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (2) , 416-425
Importance of circulating tumor DNA analysis at diagnosis in early triple-negative breast cancer patients
Background Circulating tumor DNA (ctDNA) enables non-invasive evaluation and is considered a promising tool for diagnosis, treatment selection, risk stratification, and disease monitoring. However, while the utility of ctDNA has been demonstrated in advanced-stage cancers, its detection in early breast cancer (EBC) remains limited. This study investigated the characteristics of EBC patients associated with higher ctDNA detectability. Methods A total of 101 patients with EBC were enrolled. Formalin-fixed paraffin-embedded samples (FFPEs) were obtained from biopsy tissue, and plasma samples were collected before and after neoadjuvant chemotherapy (NAC). Forty-seven breast cancer-related genes were analyzed using next-generation sequencing. The diagnostic performance of ctDNA was evaluated, and logistic regression analyses were conducted to assess the impact of clinical and molecular factors on ctDNA status. Results The most frequently identified gene was TP53 (FFPE, 66.7%; ctDNA, 46.4%), followed by PIK3CA (FFPE, 36.2%; ctDNA, 17.4%). The diagnostic performance of the three most common genes showed a sensitivity range of 11.1–58.7%, specificity of 78.3–100%, and diagnostic accuracy of 65.2–78.3%. The triple-negative breast cancer (TNBC) subtype exhibited the strongest association with ctDNA detection (odds ratio [OR] 209.50, p = 0.005) in multivariate analysis. Also, those who exhibited ctDNA clearance after NAC had a higher pathological complete response rate compared to those without clearance (38.5% vs. 11.1%, p = 0.238). Conclusions Our study highlights that ctDNA analysis can complement genetic testing from a single tissue biopsy in breast cancer patients. Furthermore, ctDNA analysis may be particularly important in patients with TNBC.
- 31 January 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (2) , 416-425
Importance of circulating tumor DNA analysis at diagnosis in early triple-negative breast cancer patients
Background Circulating tumor DNA (ctDNA) enables non-invasive evaluation and is considered a promising tool for diagnosis, treatment selection, risk stratification, and disease monitoring. However, while the utility of ctDNA has been demonstrated in advanced-stage cancers, its detection in early breast cancer (EBC) remains limited. This study investigated the characteristics of EBC patients associated with higher ctDNA detectability. Methods A total of 101 patients with EBC were enrolled. Formalin-fixed paraffin-embedded samples (FFPEs) were obtained from biopsy tissue, and plasma samples were collected before and after neoadjuvant chemotherapy (NAC). Forty-seven breast cancer-related genes were analyzed using next-generation sequencing. The diagnostic performance of ctDNA was evaluated, and logistic regression analyses were conducted to assess the impact of clinical and molecular factors on ctDNA status. Results The most frequently identified gene was TP53 (FFPE, 66.7%; ctDNA, 46.4%), followed by PIK3CA (FFPE, 36.2%; ctDNA, 17.4%). The diagnostic performance of the three most common genes showed a sensitivity range of 11.1–58.7%, specificity of 78.3–100%, and diagnostic accuracy of 65.2–78.3%. The triple-negative breast cancer (TNBC) subtype exhibited the strongest association with ctDNA detection (odds ratio [OR] 209.50, p = 0.005) in multivariate analysis. Also, those who exhibited ctDNA clearance after NAC had a higher pathological complete response rate compared to those without clearance (38.5% vs. 11.1%, p = 0.238). Conclusions Our study highlights that ctDNA analysis can complement genetic testing from a single tissue biopsy in breast cancer patients. Furthermore, ctDNA analysis may be particularly important in patients with TNBC.
- Open Access
- 15 October 2024
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 38 (19-20) , e25097
Cutoff Values for Glycated Albumin, 1,5‐Anhydroglucitol, and Fructosamine as Alternative Markers for Hyperglycemia
Background: Glycated albumin (GA), 1,5‐anhydroglucitol (1,5‐AG), and fructosamine have attracted considerable interest as markers of hyperglycemia. This study aimed to evaluate the optimal cutoff values for GA, 1,5‐AG, and fructosamine and to determine their respective diagnostic efficacies in relation to hyperglycemia.Methods: We enrolled 6012 individuals who had undergone fasting blood glucose (FBG) and Hemoglobin A1c (HbA1c) tests along with at least one alternative glycemic marker. Receiver operating characteristic (ROC) curves and the upper or lower limit of the reference range (97.5 or 2.5 percentiles) were used to ascertain the optimal cutoff values. Follow‐up data from healthy individuals were used to identify patients who developed diabetes mellitus (DM).Results: The ROC cutoff values for GA, 1,5‐AG, and fructosamine were 13.9%, 13.3 μg/mL, and 278 μmol/L, respectively, with corresponding area under the curve (AUC) values of 0.860, 0.879, and 0.834. The upper limits of the reference intervals for GA and fructosamine were 15.1% and 279 μmol/L, respectively, and the lower limit for 1,5‐AG was 5.3 μg/mL. Among the GA cutoff values, the ROC cutoff had the highest sensitivity. Analyzing the follow‐up data showed that lowering the GA cutoff from 16.0% to 13.9% identified an additional 40 people with DM progression.Conclusions: Lowering the GA cutoff values significantly increased the sensitivity of DM diagnosis and enhanced its potential as a screening marker by identifying more individuals with diabetes progression. Conversely, modifications to the cutoff values for 1,5‐AG and fructosamine did not confer any discernible diagnostic or predictive advantages.
- 15 October 2024
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 38 (19-20) , e25097
Open AccessCutoff Values for Glycated Albumin, 1,5‐Anhydroglucitol, and Fructosamine as Alternative Markers for Hyperglycemia
Background: Glycated albumin (GA), 1,5‐anhydroglucitol (1,5‐AG), and fructosamine have attracted considerable interest as markers of hyperglycemia. This study aimed to evaluate the optimal cutoff values for GA, 1,5‐AG, and fructosamine and to determine their respective diagnostic efficacies in relation to hyperglycemia.Methods: We enrolled 6012 individuals who had undergone fasting blood glucose (FBG) and Hemoglobin A1c (HbA1c) tests along with at least one alternative glycemic marker. Receiver operating characteristic (ROC) curves and the upper or lower limit of the reference range (97.5 or 2.5 percentiles) were used to ascertain the optimal cutoff values. Follow‐up data from healthy individuals were used to identify patients who developed diabetes mellitus (DM).Results: The ROC cutoff values for GA, 1,5‐AG, and fructosamine were 13.9%, 13.3 μg/mL, and 278 μmol/L, respectively, with corresponding area under the curve (AUC) values of 0.860, 0.879, and 0.834. The upper limits of the reference intervals for GA and fructosamine were 15.1% and 279 μmol/L, respectively, and the lower limit for 1,5‐AG was 5.3 μg/mL. Among the GA cutoff values, the ROC cutoff had the highest sensitivity. Analyzing the follow‐up data showed that lowering the GA cutoff from 16.0% to 13.9% identified an additional 40 people with DM progression.Conclusions: Lowering the GA cutoff values significantly increased the sensitivity of DM diagnosis and enhanced its potential as a screening marker by identifying more individuals with diabetes progression. Conversely, modifications to the cutoff values for 1,5‐AG and fructosamine did not confer any discernible diagnostic or predictive advantages.
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 35 (6)
Evaluation of clinical usefulness of HPV-16 and HPV-18 genotyping for cervical cancer screening
Cho EH, et al. J Gynecol Oncol. 2024 Mar;35:e72. https://doi.org/10.3802/jgo.2024.35.e72
- 1 January 2024
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 35 (6)
Open AccessEvaluation of clinical usefulness of HPV-16 and HPV-18 genotyping for cervical cancer screening
Cho EH, et al. J Gynecol Oncol. 2024 Mar;35:e72. https://doi.org/10.3802/jgo.2024.35.e72
- Open Access
- 1 November 2020
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 40 (6) , 500-503
Late Diagnosis of Wilson Disease, Initially Presenting as Cerebellar Atrophy Mimicking Spinocerebellar Ataxia, by Multigene Panel Testing
Min-Kyeong Kim, M.D., Kyunghoon Lee, M.D., Hee-Yeon Woo M.D., Ph.D., Hyosoon Park, M.D., Ph.D., Suho Ro, M.D., Won Tae Yoon, M.D., Ph.D., and Min-Jung Kwon, M.D., Ph.D.. Ann Lab Med 2020;40:500-3. https://doi.org/10.3343/alm.2020.40.6.500
- 1 November 2020
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 40 (6) , 500-503
Open AccessLate Diagnosis of Wilson Disease, Initially Presenting as Cerebellar Atrophy Mimicking Spinocerebellar Ataxia, by Multigene Panel Testing
Min-Kyeong Kim, M.D., Kyunghoon Lee, M.D., Hee-Yeon Woo M.D., Ph.D., Hyosoon Park, M.D., Ph.D., Suho Ro, M.D., Won Tae Yoon, M.D., Ph.D., and Min-Jung Kwon, M.D., Ph.D.. Ann Lab Med 2020;40:500-3. https://doi.org/10.3343/alm.2020.40.6.500
- Open Access
- 1 January 2020
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 10 (1) , 10
Revision of Laboratory Testing Guidelines for Initial Diagnosis of Hematologic Neoplasms
- 1 January 2020
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 10 (1) , 10
Open AccessRevision of Laboratory Testing Guidelines for Initial Diagnosis of Hematologic Neoplasms
- 24 January 2002
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 40 (7) , 689-692
Frequencies of C28Y and H63D Mutations and Transferrin Saturation Indices in the Korean Population
Hereditary hemochromatosis (HHC) is an autosomal recessive disorder that damages various organs because of the deposition of excess iron. At the human hemochromatosis (HFE) gene, two mutations of C282Y and H63D have been reported. The frequencies of C282Y and H63D mutations vary among ethnic groups. At present, the most suitable screening test for HHC is the assessment of transferrin saturation (TS). We investigated the distribution of TS and the frequencies of C282Y and H63D mutations among Koreans. TS was measured in 2152 subjects who visited the health promotion center for a checkup. The mean (+/-SD) of TS was 41.7+/-15.4%. We randomly selected 240 subjects and tested them for C282Y and H63D mutations using PCR-restriction fragment length polymorphism (RFLP). All 240 randomly selected samples were found to be G/G homozygous non-mutated for C282Y. Of the 240 subjects, 18 (7.5%) were found to be C/G heterozygous and 222 subjects were C/C homozygous non-mutated for H63D. In this study, the C282Y mutation was not found in the Korean population, and the H63D mutation showed allele frequency of 3.8%. The mean TS in this study was higher than that of Caucasians.
- 24 January 2002
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 40 (7) , 689-692
Frequencies of C28Y and H63D Mutations and Transferrin Saturation Indices in the Korean Population
Hereditary hemochromatosis (HHC) is an autosomal recessive disorder that damages various organs because of the deposition of excess iron. At the human hemochromatosis (HFE) gene, two mutations of C282Y and H63D have been reported. The frequencies of C282Y and H63D mutations vary among ethnic groups. At present, the most suitable screening test for HHC is the assessment of transferrin saturation (TS). We investigated the distribution of TS and the frequencies of C282Y and H63D mutations among Koreans. TS was measured in 2152 subjects who visited the health promotion center for a checkup. The mean (+/-SD) of TS was 41.7+/-15.4%. We randomly selected 240 subjects and tested them for C282Y and H63D mutations using PCR-restriction fragment length polymorphism (RFLP). All 240 randomly selected samples were found to be G/G homozygous non-mutated for C282Y. Of the 240 subjects, 18 (7.5%) were found to be C/G heterozygous and 222 subjects were C/C homozygous non-mutated for H63D. In this study, the C282Y mutation was not found in the Korean population, and the H63D mutation showed allele frequency of 3.8%. The mean TS in this study was higher than that of Caucasians.